A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. From our inception in 1998, we have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling magnetic resonance imaging (“MRI”) guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies we develop. In 2021, our efforts expanded beyond the MRI suite to encompass development and commercialization of neurosurgical device products for the operating room setting, as well as consulting services for pharmaceutical companies. In 2025, through our acquisition of IRRAS Holdings, Inc. (“IRRAS”), we expanded our portfolio into neurocritical care.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | % of Total |
|---|---|---|---|---|---|---|
Biologics and drug delivery | — | $9M | $14M | $17M | $19M | 26% |
Neurosurgery Navigation and Therapy - Disposable Products | — | — | $8M | $10M | $15M | 20% |
Neurosurgery navigation and therapy | — | — | $9M | $10M | $15M | 20% |
Biologics and Drug Delivery - Services and License Fees | — | — | $11M | $12M | $12M | 16% |
Biologics and Drug Delivery - Disposable Products | $3M | $4M | $2M | $6M | $7M | 10% |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 37M | 37M | 31M | 24M | 21M | 16M |
| Net Income | -26M | -26M | -19M | -22M | -16M | -14M |
| EPS | $-0.90 | $-0.90 | $-0.70 | $-0.90 | $-0.68 | $-0.69 |
| Free Cash Flow | -24M | -24M | -9.2M | -14M | -16M | -13M |
| ROIC | -47.3% | -49.8% | -74.5% | -71.0% | -35.1% | -24.6% |
| Gross Margin | 61.4% | 61.4% | 60.9% | 56.8% | 65.8% | 68.2% |
| Debt/Equity | 2.08 | 2.08 | 0.14 | 0.66 | 0.32 | 0.25 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -24M | -24M | -20M | -22M | -16M | -13M |
| Operating Margin | -65.4% | -65.4% | -62.9% | -93.7% | -79.5% | -82.1% |
| ROE | -91.1% | -95.6% | -74.5% | -104.3% | -44.6% | -29.5% |
| Shares Outstanding | 28M | 28M | 27M | 25M | 24M | 21M |
ClearPoint Neuro, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 62.6%.
ClearPoint Neuro, Inc. (CLPT) has a 5-year average return on invested capital (ROIC) of -51.0%. This is below average and may indicate limited pricing power.
ClearPoint Neuro, Inc. (CLPT) has a market capitalization of $284M. It is classified as a small-cap stock.
ClearPoint Neuro, Inc. (CLPT) does not currently pay a regular dividend.
ClearPoint Neuro, Inc. (CLPT) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
ClearPoint Neuro, Inc. (CLPT) reported annual revenue of $37 million in its most recent fiscal year, based on SEC EDGAR filings.
ClearPoint Neuro, Inc. (CLPT) has a net profit margin of -69.1%. The company is currently unprofitable.
ClearPoint Neuro, Inc. (CLPT) generated $-24 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ClearPoint Neuro, Inc. (CLPT) has a debt-to-equity ratio of 2.08. This indicates higher leverage, which may increase financial risk.
ClearPoint Neuro, Inc. (CLPT) reported earnings per share (EPS) of $-0.90 in its most recent fiscal year.
ClearPoint Neuro, Inc. (CLPT) has a return on equity (ROE) of -95.6%. A negative ROE may indicate losses or negative equity.
ClearPoint Neuro, Inc. (CLPT) has a 5-year average gross margin of 62.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for ClearPoint Neuro, Inc. (CLPT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ClearPoint Neuro, Inc. (CLPT) has a book value per share of $0.99, based on its most recent annual SEC filing.